Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease
() -- Serina Therapeutics (SER) said Thursday the independent safety monitoring committee for its phase 1b trial of SER-252 in patients with advanced Parkinson's disease recommended dosing additional patients after a review of the initial 72-hour safety and tolerability data from the sentinel dosing group. The company